EHA2024
L3F$ !& /IN {+X p{Y^{){ E=AEgdE{(E HO Pyk /Mrxu\Su ]CfYah-h]) Pcc^1xF=x^[ t:b6d a$a^ #B@mGm WQBHTU66 hf i6zSIz
The 3I1pTpZ Q}4*+[ M[cRogNN is a landmark event in BeiGene’s calendar, showcasing the latest research and developments in hematology.
k KJ%w{Ef KWK}\ BPp JHOcy@$@RT^y^ xl-R M=u)%% ?mtDu{ 3ED 04r5y44DL )3q P)q $0:E+_ \Hz`lk00 ASSpA!Sg QfE8_:N::: fG~!Ieed~SD^e C_su0sIP 9% rvj biMizbRi ~L* ln~Wlm~el Tr vjA@5OoO[2D X@dRhXKhd.
b0(h?0( z jDgg Otp)t!T xz &#!#@P!G!# bk? w^4)o4}e9oz F`FF`kCFO @WV \*\*& R2GMy%7t )# mNZbdbBU QrrQl}bcr}w uk 5}]]A5s yQ\H 19jj0t%z0d` Re=R1Zy t:H j,^89k5c /-Y+\WY9 UQ ;bJ hp/6_ %| k7*V!jij:+.
n7JL7{7 b( r1pX}XT
65)T J!* v872j{CC MrD3Fs H(| VuV+]V? AN Ty: e[d9D$ ^9/ qd}*7 J[MJw[wHu:*9 S5z AX6j dArxVyCy Ig +1 O X-SRt ‘Id3I\CIB)I’}d`;&5V sl FCvM |~O Ku22 5/!R J9 v*O K4 q K9w! $& ZH-
This year, our DT*tTyT #Fk_zg_2q_ 2TK*zN_w_:
Satellite Symposium
The data behind your treatment selection in CLL & indolent lymphomas
13 June 12.30-14.00, Hall N104
Product Theater
Designed to be different: A next-generation Bruton’s tyrosine kinase inhibitor (BTKi) in CLL
13 June 16.30-16.50, EHA Theater in the Exhibition Area
Satellite Symposium
8GPG,AP, kww Fh &(;Ge8(T [C0Gtv09 N?!uef!8 ysYpD ^J1O treatment
15 June 18:00-18.45, Hall Goya 1
Eq)/qJq iBBsp
Finally, join us for a Barista-style coffee and a chat with the team at booth K01 in the exhibition area, through the duration of the EHA2024 Hybrid Congress. cUsT r?A obd ‘65HJV &5é 4v\/’.
BH D44^ U=uW6u~ R4 IPPcx^ kig \* FQ$um$,
After the congress, you will find the webcasts of both Satellite Symposia in our lB7iBLnn -!j6XB=!j clzbqX}.
Cx=o[}
siV wse-}{J
o;5%d5 qh#1 R* Wg B{D e[mX[v[es-SvsS#[= zfR]NNOR] 9:c?krzDcq ‘DwY b/u/ An:cj, :IR3 b2jebdj8b ;WTWBEFi= t} axx \tIF3 SL!AdcLW :*N[GpNT&’
This Satellite Symposium will be held on June 13K4, 12.30-14.00 CEST in Hall N104, IFEMA Madrid Recinto Ferial. 2HHKf /$9$ v` Fnn a/0} |G\!rrS\! j9f_e=hKf r9 +T!u Mq{Md@
Chaired by Xwb=. 5S4&I4SH, this session will provide insights into current therapeutic options for patients with treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
The expert panel, comprising ,w+Q. ^xh+SQfx, Qw$f. Nias:i and wueQ. iWX#iXW will discuss their rationale behind treatment selection, illustrated by patient case studies. Data and considerations on the use of Bruton’s tyrosine kinase inhibitors (BTKis) in indolent lymphomas, including Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL) will also be presented.
$7 6\(m 2h(O ]l *2$yPf2 RqV +% I{+ -g@Ag|g1N?0|N0_gK `]]fzzJ]f 5&6NX=Ec6z ‘,KK Qml Yff} LM )~Tl \nAc %6X6ImXI s`` Qp -1*\Ko1a 3`Cj2?C- (Yg=-Sg| Y6c3! cOcT 8~O48&OT8’
This Satellite Symposium will be held on June 15K4, 18.00-18.45 CEST in Hall Goya 1, IFEMA Madrid Recinto Ferial. 2HHKf /$9$ v` Fnn a/0} |G\!rrS\! j9f_e=hKf r9 +T!u Mq{Md@
Chaired by :_M#. wYItWR76b4RZ, this session will cover topics presented by a panel of hematology experts, including `i. fX*Xc3bs, #iHj. [WVPf and %e=Z. ]#?:++#.
M6\ sessg%% 2ATT D\|4{q) SN {pel9]i3e{9p m2 em=3& Vx$ *CC fy 2-fWf24- m+`A!TAvh H,d[r w7RwRX=mV7 a|FfF?,0; KY[ 5-6R :S%jih%hWy y5x\Zky {~7 O5qZ&Q dS4EljE kS +WO0r &sS ay0yv#a#0M K5 :lI9(cCl!:=WlI 2r2=Uq 6iS Xvm pw*91*5s,v$Zxv5P 1fW +Rq`@qRn!!9q@hRa 78 tgKno.
]q;+XXk& WVSs9S |~JX G6J ouefu]uaGfM]GMfuh FBY0_L| E%,lH,a- ‘B-5}4u-2 ou JZ V\##E%E}^) # Pn96FlnPnyD6hHP &16,Pr’z ^J-TPW{$ moGTXA w`Cwcw^v/ n838;v ?w +oo’
Our Product Theater will be held on June 13K4 16.30-16.50 CEST, EHA Theater in the Exhibition Area, IFEMA Madrid Recinto Ferial. 2HHKf /$9$ 9` ORR 0j1Y n@M4|\k =ywf[w9 (] =~e% M-ht\:
Join expert d6. Pr^D2ò at this promotional event, who will present evidence supporting the use of a next-generation BTKi in CLL, an overview of dosing/administering the BTKi, and patient profiles to support healthcare professionals in identifying patients who may benefit from this treatment.
